The successful achievement of the primary endpoint in a Phase 3 study is a significant milestone for any pharmaceutical company. This positive result is likely to boost investor confidence, potentially leading to a short-term increase in Agios Pharmaceuticals' stock price. Additionally, the improvements in health-related quality of life measures and patient-reported outcomes further validate the efficacy of mitapivat, which could enhance the company's market position and future revenue prospects.